Dr. Lakshmana M. Kooragayala, MD

Dr. Kooragayala practices at Marietta Eye Surgery Center in Marietta, Georgia.

Dr. Kooragayala's NPI, 1497757496, was assigned on August 10, 2005. Dr. Kooragayala holds Georgia license 056191.

Dr. Kooragayala's primary practice is Marietta Eye Surgery Center, at 895 Canton Road, Bldg 200, Suite 300, Marietta, GA 30060. The practice phone is (770) 427-8111.

Dr. Kooragayala's primary practice is Marietta Eye Surgery Center in Marietta, Georgia. Dmand AI also links Dr. Kooragayala to 1 group practice or clinic and 1 medical group, each named with a free account. Dr. Kooragayala's employer is on file too: a surgery center (asc).

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kooragayala practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Kooragayala's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Kooragayala is licensed in Georgia.

CMS data shows 16,901 Medicare services from Dr. Kooragayala across 19 procedure codes in 2024, for 728 Medicare patients. Medicare paid $1,959,988 for them. Every service was in an office.

CMS counts 728 Medicare patients who saw Dr. Kooragayala in 2024. The largest group is 75 to 84, with 286 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 7% are also on Medicaid. Their average risk score is 1.61, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kooragayala's median patient age at 73, with 54% women.

In 2024, Dr. Kooragayala wrote 382 Medicare Part D claims for 136 patients. 65% of them were for generic drugs. CMS names the drug for 280 of them, across 5 drugs with 11 or more claims each, at $5,910 in total drug cost. In 2023, CMS named 352 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Kooragayala for performance year 2024, reported through an alternative payment model (APM). Dr. Kooragayala accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links Dr. Kooragayala to 2 clinical trials. Conditions studied include Macular Degeneration, Retinal Vein Occlusion and Retinal Degeneration. Open Payments lists research payments to Dr. Kooragayala that name 1 trial.

CMS Open Payments shows 264 general payments to Dr. Kooragayala from 28 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 98% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $1,313. It also lists 8 research payments totaling $2,096 in 2019, naming 1 clinical trial.